The Score Right Now Is: Opioid Crisis 1, PixarBio 0
August 19, 2018
Forbes interviewed David Axelrod—a Partner in the firm’s Securities Enforcement and Corporate Governance Litigation and a former Supervisory Trial Counsel at the U.S. Securities and Exchange Commission's (SEC) Philadelphia Regional Office—for an article exploring enforcement actions against PixarBio, which has a non-opioid pain reliever in development.
Read the full article here. (Subscription may be required.)
Subscribe to Ballard Spahr Mailing Lists
Get the latest significant legal alerts, news, webinars, and insights that affect your industry.Subscribe